Equities analysts predict that Chiasma Inc (NASDAQ:CHMA) will report earnings of ($0.22) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Chiasma’s earnings. The lowest EPS estimate is ($0.28) and the highest is ($0.17). Chiasma posted earnings per share of ($0.32) during the same quarter last year, which indicates a positive year over year growth rate of 31.3%. The firm is scheduled to announce its next earnings results on Friday, March 13th.
On average, analysts expect that Chiasma will report full-year earnings of ($1.03) per share for the current fiscal year, with EPS estimates ranging from ($1.08) to ($0.92). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.11) per share, with EPS estimates ranging from ($1.72) to ($0.67). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Chiasma.
Several research firms recently commented on CHMA. ValuEngine upgraded Chiasma from a “sell” rating to a “hold” rating in a research report on Saturday, January 4th. Piper Sandler lifted their price target on Chiasma from to and gave the stock an “overweight” rating in a research report on Tuesday, January 14th. Finally, HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of Chiasma in a research report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Chiasma presently has an average rating of “Buy” and an average price target of $11.70.
In other Chiasma news, Director Roni Mamluk sold 82,186 shares of the business’s stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $4.54, for a total transaction of $373,124.44. Following the completion of the transaction, the director now owns 82,186 shares in the company, valued at $373,124.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 8.30% of the stock is owned by insiders.
Large investors have recently made changes to their positions in the business. Voya Investment Management LLC raised its stake in shares of Chiasma by 20.3% during the third quarter. Voya Investment Management LLC now owns 12,713 shares of the biotechnology company’s stock valued at $63,000 after acquiring an additional 2,149 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Chiasma by 11.4% during the third quarter. Rhumbline Advisers now owns 22,218 shares of the biotechnology company’s stock valued at $110,000 after acquiring an additional 2,265 shares in the last quarter. Cubist Systematic Strategies LLC raised its stake in Chiasma by 31.2% in the fourth quarter. Cubist Systematic Strategies LLC now owns 13,022 shares of the biotechnology company’s stock worth $65,000 after buying an additional 3,099 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Chiasma by 3.9% in the fourth quarter. Bank of New York Mellon Corp now owns 103,686 shares of the biotechnology company’s stock worth $515,000 after buying an additional 3,888 shares in the last quarter. Finally, Quantitative Systematic Strategies LLC raised its stake in Chiasma by 41.5% in the fourth quarter. Quantitative Systematic Strategies LLC now owns 19,817 shares of the biotechnology company’s stock worth $98,000 after buying an additional 5,813 shares in the last quarter. Institutional investors and hedge funds own 77.39% of the company’s stock.
Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.
See Also: What is the Current Ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.